ClinicalTrials.gg
CompletedNCT06744660Updated Nov 3, 2026Results posted

Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test

An interventional study of Aptitude Medical Systems Metrix COVID Test in COVID-19 and COVID, sponsored by Aptitude Medical Systems. Completed at 1 site in United States. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Aptitude Medical Systems · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 3, 2026Now CompletedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
697
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
257th of 1,322
697 · median 92
Started
2024
with 72 others
No phase
428 of 1,860
22 open now
Registered
1,781st of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 257th largest by enrollment of the 1,322 interventional ones that give a count, is one of 73 that started in 2024, is one of 428 with no phase, and was the 1,781st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 2 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The Metrix COVID Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix COVID Test for the detection of SARS-CoV-2 AN swab samples. Additional sites may be added to the study in order to meet minimum subject/sample enrollment requirements and geographic prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2.

Read the detailed description

The Metrix COVID Test will be evaluated for OTC use in a home use testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix COVID Test for the differential detection of SARS-CoV-2 in AN swab samples. Additional sites may be added to the study in order to meet minimum subject/sample enrollment requirements and geographic prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for detection of SARS-CoV-2.

The candidate device, Metrix COVID Test, will be evaluated with AN swab sample types. Each Metrix COVID Test kit contains all supplies needed to test AN swab samples, including a corresponding QRI for detailed instructions.

This OTC study will take place in simulated home environments which will be set up within or near clinical settings (e.g., urgent care facilities). The study will enroll symptomatic subjects only. Candidate samples will be self-collected by participants (or collected by a guardian for participants under the age of 14 years) and comparator samples will be collected by a healthcare practitioner with informed consent and Institutional Review Board (IRB) approval. Each sample will be coded for confidentiality.

For each participant, a comparator NP swab sample will be obtained by a healthcare practitioner after testing with the candidate device. This NP swab will be tested with the FDA-cleared SARS-CoV-2 assay according to the IFU and will serve as the primary comparator for swab samples. An additional AN swab sample will be collected and stored frozen and dry for later analysis to support future research validation studies.

No results from the investigational test or comparator testing will be used for clinical diagnosis, management of study participants, or to make treatment decisions.

Test results from the Metrix COVID Test (investigational test) will be compared to the test results generated from the comparator assay.

No investigational test results will be reported to a third party or used for any treatment decisions.

This work is supported by funding provided by the Biomedical Advanced Research and Development Authority (BARDA).

03

Conditions studied

  • COVID-19
  • COVID

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant or guardian understands and is able and willing to provide written , and assent where applicable, prior to study enrollment.
  2. Male or female aged 2 years or older
  3. Participant is currently exhibiting fever, or one or more symptoms of respiratory tract infection (such as, but not limited to, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea). Participant must still be exhibiting symptoms on the day of sample collection.
  4. Participant or guardian agrees to read, and is able to read with understanding, the AN swab QRI prior to beginning the operation of each of the Metrix COVID-19 Test.
  5. Participant or guardian is able and willing to contribute the required swab samples for testing and understands and is able and willing to sign the study informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Participant does not understand and/or is not able and willing to sign the study and/or assent.
  2. Participant or guardian is not able to comply with nasal swab collection requirements following the QRI.
  3. Participant has previously provided a sample for the study.
  4. Participant is not able to tolerate sample collection.
  5. Participant is currently undergoing antiviral treatment such as baloxavir marboxil (trade name Xofluza®), oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®).
  6. Participants currently undergoing treatment and/or within the past thirty (30) days with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or receiving convalescent plasma therapy for SARS-CoV-2.
  7. Participants who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection.
  8. Participants who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.
  9. Participants who do not understand/read the English language.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
697 participants (actual)

Study arms

  • Experimental
    OTC Study

    This OTC study will take place in simulated home environments which will be set up within or near clinical settings (e.g., urgent care facilities). The study will enroll symptomatic subjects only. Candidate samples will be self-collected by participants (or collected by a guardian for participants under the age of 14 years) and comparator samples will be collected by a healthcare practitioner with informed consent and Institutional Review Board (IRB) approval. Each sample will be coded for confidentiality.

    Diagnostic Test: Aptitude Medical Systems Metrix COVID Test

Interventions

  • Diagnostic testAptitude Medical Systems Metrix COVID Test

    The Metrix COVID Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2 via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.

06

What researchers measure

Primary outcomes

  1. Qualitative Detection of RNA From SARS-CoV-2 and Measurement of Positive/Negative Percent Agreement With FDA-cleared Comparator Test

    Qualitative detection of RNA from SARS-CoV-2 in unprocessed AN swab samples. Primary objective of this study is to evaluate the performance (positive percent agreement, negative percent agreement and 95% confidence intervals for upper and lower bounds) of the Metrix COVID/Flu Test for the qualitative detection of SARS-CoV-2 viral RNA using AN swab samples. Higher percent agreement is better, with a minimum of 95% for PPA, and 99% for NPA. Comparator testing will be performed to determine the status of each sample for comparison to results produced by the candidate test. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay that detects SARS-CoV-2.

    Time frame: 25 minutes

07

Results

Posted Nov 3, 2026

Participant flow

Patients were recruited who displayed symptoms similar to COVID infection, themselves or a guardian who could understand English, and were greater than the age of 2 years old.

Participant flow — Overall Study
MilestoneOTC Study
Started697
Completed682
Not completed15
Withdrew: Withdrawal by subject5
Withdrew: Protocol violation5
Withdrew: Invalid/no result5

Outcome measures

PrimaryQualitative Detection of RNA From SARS-CoV-2 and Measurement of Positive/Negative Percent Agreement With FDA-cleared Comparator Test

Qualitative detection of RNA from SARS-CoV-2 in unprocessed AN swab samples. Primary objective of this study is to evaluate the performance (positive percent agreement, negative percent agreement and 95% confidence intervals for upper and lower bounds) of the Metrix COVID/Flu Test for the qualitative detection of SARS-CoV-2 viral RNA using AN swab samples. Higher percent agreement is better, with a minimum of 95% for PPA, and 99% for NPA. Comparator testing will be performed to determine the status of each sample for comparison to results produced by the candidate test. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay that detects SARS-CoV-2.

Time frame:
25 minutes
Reported as:
Number · Percentage of agreement
Qualitative Detection of RNA From SARS-CoV-2 and Measurement of Positive/Negative Percent Agreement With FDA-cleared Comparator Test
Percentage of agreementOTC Study
Positive Percent Agreement - SARS-CoV-295.6 (87.8 to 98.5)
Negative Percent Agreement - SARS-CoV-299.5 (98.6 to 99.8)

Adverse events

Collected over From enrollment until end of test, ~1 hour. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTC Study0/682 (0%)0/682 (0%)0/682 (0%)

Baseline characteristics

These were the number of evaluable subjects for the data analyses.

Age, Categorical
Age, Categorical(Participants)OTC Study
<=18 years73
Between 18 and 65 years578
>=65 years31
Sex: Female, Male
Sex: Female, Male(Participants)OTC Study
Female456
Male226
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OTC Study
Race Demographics — Black or African American225
Race Demographics — White or Caucasian427
Race Demographics — Asian8
Race Demographics — Other/Prefer Not to Answer/Unkown22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OTC Study
Ethnicity Demographics — Hispanic or Latino214
Ethnicity Demographics — Other/Prefer Not to Answer/Unkown468
08

Study locations

1 site
  • AFC Urgent Care - Trussville
    Birmingham, Alabama 35235, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Sep 2025, 11 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 138 industry-sponsored interventional studies with no phase under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 11 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Sep 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 20, 2024
StartActual
Oct 17, 2024
Primary completionActual
Sep 18, 2025
CompletionActual
Sep 1, 2026was Dec 2025
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 3, 2026
Results
Results posted
posted Nov 3, 2026
Sites
1 site added, 3 sites removed
Show site
  • AFC Urgent Care - Trussville · Birmingham, United States
Show 3 removed
  • AFC Montclair · Birmingham, United States
  • AFC Madison · Madison, United States
  • PPU Mid City · Baton Rouge, United States
Nov 3, 2026
Study completion
Dec 1, 2025→Sep 1, 2026 (actual)
Nov 3, 2026
Enrollment
1000 (estimated)→697 (actual)
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedQualitative detectionDetection of RNA fromFrom SARS-CoV-2 and Measurement of Positive/Negative Percent Agreement withWith FDA-cleared comparator testComparator TestTime frame: 25 minutes
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Recruiting→Completed
    Results posted
    1 site added, 3 sites removed
    Show site
    • AFC Urgent Care - Trussville · Birmingham, United States
    Show 3 removed
    • AFC Montclair · Birmingham, United States
    • AFC Madison · Madison, United States
    • PPU Mid City · Baton Rouge, United States
    Study completion Dec 1, 2025→Sep 1, 2026 (now actual)
    Enrollment 1000 (estimated)→697 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedQualitative detectionDetection of RNA fromFrom SARS-CoV-2 and Measurement of Positive/Negative Percent Agreement withWith FDA-cleared comparator testComparator TestTime frame: 25 minutes
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06744660
Lead sponsor
Aptitude Medical Systems
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Oct 17, 2024
Primary completion
Sep 18, 2025
Completion
Sep 1, 2026
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion